Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 92

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 3
Chunk 92
---
 by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
 Natural disasters could severely disrupt our operations and hurt our financial condition. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period

of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans.
 Risks Related to the ADSs
 The price of our ADSs may be volatile and may fluctuate due to factors beyond our control.
 The trading price of the ADSs has fluctuated, and is likely to continue to fluctuate substantially. The trading price of those securities depends on a number of factors, including those described in this “Risk Factors” section, many of which are beyond our control and may not be related to our operating performance. In addition, although the ADSs are listed on the Nasdaq Capital Market, or Nasdaq, we cannot assure you that a trading market for those securities will be maintained.
 Since the ADSs were sold in our initial public offering in October 2017 at a price of $375.00 per ADS, the closing price per ADS has ranged as low as $0.79 and as high as $746.00 through March 19, 2025. The market price of our ADSs may fluctuate significantly due to a variety of factors, many of which are beyond our control, including:
 •positive or negative results from, or delays in, testing and clinical trials by us, collaborators or competitors;
 •technological innovations or commercial product introductions by us or competitors;
 •changes in government regulations;
 •developments concerning proprietary rights, including patents and litigation matters;
 •public concern relating to the commercial value or safety of NUC-7738 or NUC-3373 or any of our other potential product candidates;
 •financing, collaborations or other corporate transactions;
 •publication of research reports or comments by securities or industry analysts;
 •general market conditions in the biotechnology or pharmaceutical industries or in the economy as a whole;
 •the loss of any of our key scientific or senior management personnel;
 •sales of our ADSs